等待开盘 10-06 09:30:00 美东时间
+0.032
+0.06%
- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1- All pre-specified primary and
05-12 19:32